Secukinumab

Details

Files

Generic Name:

Secukinumab

Project Status:

Complete

Therapeutic Area:

Arthritis, psoriatic

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Call for patient/clinician input open:

January 21, 2016

Brand Name:

Cosentyx

Project Line:

Reimbursement Review

Project Number:

SR0476-000

Call for patient/clinician input closed:

March 11, 2016

NOC Status at Filing:

Pre NOC

Performance Metric:

Achieved

Submission Type:

Initial

Indications:

Arthritis, psoriatic

Recommendation Type:

Reimburse with clinical criteria and/or conditions

Final Recommendation:

August 23, 2016

Files

Submission Status Report View PDF

Recommendation and Reasons View PDF

Clinical Report View PDF

Pharmacoeconomic Report View PDF

Patient Group Input Submissions View PDF

Last Updated : January 21, 2016